COMMENTARY

Japanese Drug Makers Working to Increase Pace of Drug Discovery by Optimizing Operations at Research Centers

August 18, 2014
Drug makers are carrying out organizational revamps at their drug discovery research centers. With the discovery of new drugs becoming harder than ever, what are they doing to surmount the challenges involved? Sharpening Core Competence “What’s unique about our drug…

To read the full story

COMMENTARY

By Sakura Kono

Japan’s general trading houses are steadily becoming a force to be reckoned with in the pharmaceutical industry — and not…

A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

By Philip Carrigan

In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…

By Ken Yoshino

The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…